PRO-6E

• Description:

  PRO-6E is an oral active PROTAC based on Cereblon ligand, and induces the degradation of MET with maximum degradation of 81.9% at 1 μM in MKN-45 cells. PRO-6E inhibits tumor growth in vivo and in vitro. PRO-6E induces cell apoptosis and induces cell arrest (Sturcture Note: (Blue: Cereblon ligand (HY-103596), Black: linker; Pink: ALK/c-Met inhibitor Crizotinib (HY-50878) ) [1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; c-Met/HGFR; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pro-6e.html

• Concentration:

  10mM

• Purity:

  99.85

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C1C2=C(OCCCCCCCC(N3CCC(N4C=C(C5=CN=C(N)C(O[C@@H](C6=C(C(F)=CC=C6Cl)Cl)C)=C5)C=N4)CC3)=O)C=CC=C2C(N1C7C(NC(CC7)=O)=O)=O

• Molecular Formula:

  C42H44Cl2FN7O7

• Molecular Weight:

  848.75

• References & Citations:

  [1]Chen JJ, et al. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation. Cancer Sci. 2023;114 (5) :1958-1971.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2353493-69-1]